Anti-Fibrinolytic Drugs - Malaysia

The Anti-Fibrinolytic Drugs market in Malaysia is expected to achieve a revenue of US$24.00m MYR by 2024.
It is projected to exhibit an annual growth rate (CAGR 2024-2029) of 5.31%, leading to a market volume of US$31.09m MYR by 2029.
In terms of global comparison, United States will generate the highest revenue, reaching US$9.86bn MYR in 2024.
Malaysia's market for Anti-Fibrinolytic Drugs is witnessing a surge in demand due to the rising prevalence of cardiovascular diseases.

Definition:
The Anti-Fibrinolytics market covers drugs which help blood to clot. They are used to treat and prevent bleeding episodes of patients with hemophilia. Moreover, anti-fibrinolytics are used before or during certain surgeries. In doing so, the usage of blood products, such as fresh frozen plasma, as well as the associated risks of infections and/or anaphylactic reactions can be avoided.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Roche, Takeda, Novo Nordisc, Sanofi, Bayer

Inhibitors of fibrinolysis
Drugs to treat hemophilia

Anti-coagulants
Anti-hypertensives
Wound care

The Anti-Fibrinolytic Drugs market in Malaysia has been experiencing steady growth over the past few years.

Customer preferences: Customers in Malaysia are increasingly opting for Anti-Fibrinolytic Drugs due to the rising prevalence of bleeding disorders and the growing awareness about the benefits of these drugs. Additionally, the aging population in the country has also resulted in an increase in demand for these drugs.

Trends in the market: One of the major trends in the Anti-Fibrinolytic Drugs market in Malaysia is the increasing adoption of generic drugs. This is mainly due to the cost-effectiveness of generic drugs as compared to their branded counterparts. Another trend in the market is the growing focus on research and development activities by key market players to develop innovative Anti-Fibrinolytic Drugs.

Local special circumstances: The Malaysian government has been actively promoting the use of generic drugs to reduce healthcare costs in the country. This has resulted in an increase in the adoption of generic Anti-Fibrinolytic Drugs in the market. Additionally, the country has a well-established healthcare infrastructure that is capable of providing quality healthcare services to its citizens.

Underlying macroeconomic factors: The growing healthcare expenditure in Malaysia is one of the major macroeconomic factors driving the growth of the Anti-Fibrinolytic Drugs market in the country. Additionally, the increasing awareness about bleeding disorders and the benefits of Anti-Fibrinolytic Drugs is also contributing to the growth of the market. The aging population in the country is another factor that is driving the demand for these drugs.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

Bleeding disorders affect the clotting of blood and can result in excessive bleeding inside and outside of the body. Bleeding disorders are almost always inherited and common symptoms include easy bruising, frequent nosebleeds, heavy menstrual bleeding, and excessive bleeding from small cuts. Treatments vary depending on the type of disorder, but may include factor replacement therapy, iron supplementation, topical products or sprays, or blood transfusions. The most common types of bleeding disorders are hemophilia A and B and von Willebrand disease. In 2022, there were around 257,146 people worldwide who had been diagnosed with hemophilia and 100,505 who had been diagnosed with von Willebrand disease.